Post
Pharmaceutical compliance management software for the pharmaceutical industry
Pharmaceutical and biotechnology companies must maintain quality and meet stringent regulatory standards throughout their operations. Pharmaceutical compliance management software is …
NIH team develops AI tool to predict cancer drug response
Researchers at the National Cancer Institute, a unit of the National Institutes of Health (NIH) in the US, have developed …
FDA approves Takeda’s ENTYVIO SC for Crohn’s disease
The US Food and Drug Administration (FDA) has granted approval for Takeda’s ENTYVIO subcutaneous (SC) administration as a maintenance therapy …
The next phase for mRNA: Looking beyond COVID-19
In early 2020, with the world ground to a halt, long-studied messenger RNA (mRNA) technology helped scientists develop COVID-19 vaccines …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer. According to …
NIH team develops AI tool to predict cancer drug response
Researchers at the National Cancer Institute, a unit of the National Institutes of Health (NIH) in the US, have developed …
FDA approves Takeda’s ENTYVIO SC for Crohn’s disease
The US Food and Drug Administration (FDA) has granted approval for Takeda’s ENTYVIO subcutaneous (SC) administration as a maintenance therapy …
The next phase for mRNA: Looking beyond COVID-19
In early 2020, with the world ground to a halt, long-studied messenger RNA (mRNA) technology helped scientists develop COVID-19 vaccines …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Solid Tumor. According to …
Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa. According to GlobalData, …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hepatocellular Carcinoma. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer. According …